168 related articles for article (PubMed ID: 37860559)
21. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis.
Madhavan D; Wallwiener M; Bents K; Zucknick M; Nees J; Schott S; Cuk K; Riethdorf S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Surowy H; Burwinkel B
Breast Cancer Res Treat; 2014 Jul; 146(1):163-74. PubMed ID: 24838941
[TBL] [Abstract][Full Text] [Related]
22. Serum cell-free DNA concentrations and integrity analysis of colorectal cancer patients before and after surgery.
Cao G; Xie Y; Jiang X; Tian X; Wang D; Sun Y
Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):44-51. PubMed ID: 31472046
[TBL] [Abstract][Full Text] [Related]
23. A Case-Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection.
Bortul M; Giudici F; Tierno D; Generali D; Scomersi S; Grassi G; Bottin C; Cappelletti MR; Zanconati F; Scaggiante B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239866
[TBL] [Abstract][Full Text] [Related]
24. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of plasma cfDNA concentration and integrity in breast cancer patients.
Miao Y; Fan Y; Zhang L; Ma T; Li R
Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):64-72. PubMed ID: 31472049
[TBL] [Abstract][Full Text] [Related]
26. Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer.
Soliman SE; Alhanafy AM; Habib MSE; Hagag M; Ibrahem RAL
Biochem Biophys Rep; 2018 Sep; 15():45-51. PubMed ID: 29984326
[TBL] [Abstract][Full Text] [Related]
27. Circulating free DNA integrity index and promoter methylation of tumor suppressor gene P16, DAPK and RASSF1A as a biomarker for oropharyngeal squamous cell carcinoma.
Kumari S; Mishra S; Anand N; Hadi R; Rastogi M; Husain N
Pathol Res Pract; 2023 Jun; 246():154489. PubMed ID: 37150134
[TBL] [Abstract][Full Text] [Related]
28. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
29. Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study.
Wang X; Zhi X; Zhang Y; An G; Feng G
J Thorac Dis; 2016 Jul; 8(7):1645-52. PubMed ID: 27499953
[TBL] [Abstract][Full Text] [Related]
30. Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis.
Wen Z; Huang Y; Ling Z; Chen J; Wei X; Su R; Tang Z; Wen Z; Deng Y; Hu Z
Dis Markers; 2020; 2020():4716793. PubMed ID: 33488842
[TBL] [Abstract][Full Text] [Related]
31. Cancer stage-dependent alterations in cell-free DNA in patients with colorectal cancer.
Pu W; Xiao L; Zhou C; Zhong F; Wu Y; Gong W; Lv X; Zhuang Z; Wang H; Bian H; Wang J; Zhang R; Li K; Xing C
J BUON; 2021; 26(1):109-115. PubMed ID: 33721440
[TBL] [Abstract][Full Text] [Related]
32. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
[TBL] [Abstract][Full Text] [Related]
33. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer.
Wang L; Wang D; Zheng G; Yang Y; Du L; Dong Z; Zhang X; Wang C
Int J Biol Markers; 2016 Feb; 31(1):e80-7. PubMed ID: 26560853
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the cell-free DNA integrity index as a liquid biopsy marker to differentiate hepatocellular carcinoma from chronic liver disease.
Kumar S; Nadda N; Paul S; Gamanagatti S; Dash NR; Vanamail P; Saraya A; Shalimar ; Nayak B
Front Mol Biosci; 2022; 9():1024193. PubMed ID: 36483538
[No Abstract] [Full Text] [Related]
35. Alter circulating cell-free DNA variables in plasma of ovarian cancer patients.
Yu Z; Qin S; Wang H
J Obstet Gynaecol Res; 2019 Nov; 45(11):2237-2242. PubMed ID: 31502389
[TBL] [Abstract][Full Text] [Related]
36. Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence.
Fawzy A; Sweify KM; El-Fayoumy HM; Nofal N
J Egypt Natl Canc Inst; 2016 Dec; 28(4):235-242. PubMed ID: 27634416
[TBL] [Abstract][Full Text] [Related]
37. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
[TBL] [Abstract][Full Text] [Related]
38. Investigation of Efficacy Evaluation Comparison of cfDNA and CEA in Colorectal Cancer.
Yu D; An G; Xu L
Clin Lab; 2016 Oct; 62(10):1947-1953. PubMed ID: 28164530
[TBL] [Abstract][Full Text] [Related]
39. The level and integrity of plasma circulating cell-free DNA in patients with primary multiple myeloma.
Shen Q; Cen H; Jiang J; Cong Z; Zhou Y; Huang X; Zhu L; Jiang Q; Xue C
Transl Cancer Res; 2022 Nov; 11(11):4137-4147. PubMed ID: 36523306
[TBL] [Abstract][Full Text] [Related]
40. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
